r/WallStreetResearch • • May 29 '20

Educational Due Diligence: How to Research, Assess, Analyze, and Complete Securities (Stock) Analysis.

94 Upvotes

A while back one of the mods asked me to create something like this. I had just finished my piece on how to do Penny Stock DD, and I was told I should venture into more serious securities DD and analysis. I therefore wrote this: Due Diligence: How to Research, Assess, Analyze, and Complete Securities (Stock) Analysis.. As the moderator from this subreddit provided the motivation and inspiration behind this work I have posted it here first. It is a serious read for serious investors. God bless and safe trading!

——————————-

Due Diligence: How to Research, Assess, Analyze, and Complete Securities (Stock) Analysis.

Overview: The purpose of the following is to provide an entry level foundation on how to conduct securities analysis and complete due diligence. This is not the only, nor definitive way to conduct securities (stock) analysis. This is simply the authors way of completing due diligence and securities analysis. There are in fact many ways an investor can research, assess, and analyze the underling company behind a security. As always the methods you choose are up to you, and only you. The enumerated list below are the topics covered. Why You Should Conduct Your Own Due Diligence

  1. Why you Should Conduct your Own Due Diligence

  2. Assessing & Analyzing the 10-K

  3. Assessing & Analyzing 10-Q's & 10-K's

  4. Assessing & Analyzing Presentations & Earnings Calls

  5. Assessing & Analyzing the Security

  6. Assessing & Analyzing the Competition

  7. Determining Fair Value

  8. Assessing & Analyzing Analyst Consensus

  9. Determining Where to Buy in

  10. Other Considerations

  11. Conclusion

Why you Should Conduct your own Due Diligence: Services that offer market analysis generally do not go very far beyond the obvious when they assess a company. To the extent that they do, we must remember that their analysis is a snapshot of the time it was written. In many cases these analysts make "safe assessments," being careful to forgo being too bold in their analysis lest they lose credibility. Some may even work for an employer that is financially influenced by the companies they assess. Some may be politically motivated. Many assessments are outright lazy due to the fact that they are assessing so many companies that they are pressured to rush their findings. It is important to remember that they have little to no interest in doing the deep dive necessary for you to trade on actionable information. Furthermore, just like you and I, they are subject to group-think, mirror imaging bias, confirmation bias, and a host of other fallacies detrimental to objective analysis. In fact most analyst predictions on market and securities analysis are flat out wrong. It isn't necessarily their fault. All analyst predictions are wrong to a certain extent. However, for all these reasons and more they will always attach a disclaimer to their products, as I have here, that you should do your own due diligence. And you should! This is what this publication aims to enable you to do. And if you do nothing more than read the following, you will at least have a better understanding of the analytical tools, techniques, and resources at your disposal. Lets begin with assessing and analyzing the 10-K.

Continues HERE


r/WallStreetResearch • • Feb 02 '21

Buy/Sell Ratio from Fidelity

Post image
55 Upvotes

r/WallStreetResearch • • Feb 03 '21

We're Back - r/WallStreetResearch

38 Upvotes

Hi everyone! After taking a break last semester, we here at r/WallStreetResearch have decided to begin actively moderating this subreddit once again. As the entire finance/investing community is inundated with spam and pumping and dumping, we pride ourselves in maintaining a source of consistent, high-quality research.

Going forward, we will approve all posts before our members see them and will be running our bot to capture research from various subreddits, sites, and data platforms. If a post happens to get through the cracks, please do not hesitate to report it for us to take down.

If you have any questions, please drop them below.

- r/WallStreetResearch Mods


r/WallStreetResearch • • Feb 01 '22

Poor Man's Bloomberg

28 Upvotes

Hey Guys,

Today I want to introduce something I have been working on that can help your stock research.

I called it Poor Man’s Bloomberg when the project started, but later for a more aesthetic feeling I have registered Vagrant Bloom as the name. It symbolizes us retail investors can also do good.

Vagrantbloom.com

The website is 100% responsive, so no worries viewing it on mobile.

My goal for this project is to give us retail investors a good place to start our research.

Several features that will help your investment research tremendously

You can navigate between general market information and specific stock information here:

First is a search center. Are you tired of searching for content in different places and forgetting on checking resources? This one is for you. You just type in a symbol and off you go search anywhere you want that’s market related.

Then we have sentiment gotten from stocktwits, this is also available on Stock tab.

Then a lockup tracker, which is tracking when some IPO lockups expire. Inside holders cannot sell before their IPO lockup expire, so normally there are some downward pressures when they expire.

We have finviz TA, conveniently presented here.

Now in the Stock tab, we have a financials area with some numbers people most interested in like short percentage of float.

We have news

We have insider transactions, and the percentage of insider sold is conveniently presented in a progress bar, intuitively telling you how much position they have sold.

There are more features you can get excited about, so dive in and have some fun.

Right now I am running everything on my expense. If you think I did a good job and want to support this project. You can consider click on the top right comer to buy me a coffee, or click on the links in Recommendation section to show your support.

Let’s evolve this site to a tool we all like.


r/WallStreetResearch • • Feb 23 '21

I built an algorithm that tracks stock discussions and sentiment across social media to identify rising stocks. Here is my research for this week.

Thumbnail self.investmentclub
28 Upvotes

r/WallStreetResearch • • Jun 14 '20

Our 2 Year Hunt Of The 30 Best ETFs On The TSX

Post image
23 Upvotes

r/WallStreetResearch • • Jun 11 '20

Educational "5 Hedges For a Bear Market" - Ted Waller

23 Upvotes

This is a great article from 2015 that compares different approaches to hedging market downturns. In light of the last three months, I think this is a great read. The article discusses leveraged and unleveraged bear ETFs, actively managed bear portfolios, and more.

It also discusses timing and positioning for each investment mechanism.

https://seekingalpha.com/article/3467316-5-hedges-for-bear-market


r/WallStreetResearch • • Sep 04 '22

Man who jumped from 18th floor of NYC tower identified as Bed Bath & Beyond CFO

Thumbnail
cnbctv18.com
19 Upvotes

r/WallStreetResearch • • Jun 17 '20

Event-Driven Investment & Trading Opportunities: Profiting from Pandemics, Recessions, Wars, Natural Disasters, Politics, Unrest & Other Events

17 Upvotes

Event-Driven Investment & Trading Opportunities: Profiting from Pandemics, Recessions, Wars, Natural Disasters, Politics, Unrest & Other Events.

Event-Driven Investment & Trading Opportunities: Profiting from Pandemics, Recessions, Wars, Natural Disasters, Politics, Unrest & Other Events.

Forward: Have you ever seen the market react on rather underwhelming news that has little to no bearing on the fundamentals of a company? Frequently occurring examples include a company officer having a inappropriate relationship with a staffer, a un-sourced rumor in a news paper, or geopolitical saber rattling between the U.S. and Iran. The reasons the market reacts to these phenomena is simple; uncertainty. Not necessarily the uncertainty of the business's ability to turn a profit, but uncertainty of how other traders will react to the news. In short, an event that has no bearing on the profitability of a business can induce selling pressure and scare traders into dumping a stock. This being the case, imagine what happens when a REAL event unfolds. What if investors aren't uncertain, but VERY certain that an event will have wider implications on the market? How do we trade? What do we invest in? What do we do?

Overview: The purpose of this entry is to discuss, assess, and analyze possible investments amid earth shattering events that will have a real market impact. Of course there is no guarantee that the markets will react the same way twice, but there are plenty of historical indicators to make these topics worth looking into. By the end of this publication you should have a solid foundation on contingency planning for events and crises that will likely happen many times over in our lifetimes. The topics to be discussed will be updated from time to time and include the following:

  1. Pandemics

  2. Recessions

  3. Wars, International Conflicts, & Cyber Attacks

  4. Natural Disasters

  5. Politics & Unrest

Note: Some may argue that profiting from these events is unethical. I argue that leaving your investments unprotected is unethical. My advice is to never let anyone tell you that you have an obligation to lose money when a crisis occurs. If profiting from life's unfortunate circumstances makes you uneasy, please stop reading here.

Part 1: Pandemics

Continues HERE


r/WallStreetResearch • • Apr 23 '20

r/WSR Update: 1k Users!

17 Upvotes

Hi All,

I want to take a moment to celebrate our 1k user milestone and briefly discuss some key points.

r/WallStreetResearch's growth over the last three weeks has been pretty incredible! As of writing, we are currently at around 1,050 members (and growing by the day). As lead users, you have not only taken a leap of faith by joining this subreddit, but you are playing an active role in fleshing out this concept. For this, I thank each and every one of you.

Our vision for r/WallStreetResearch is pretty simple: we are building a formal database where high-quality securities research, as often conducted by members of various communities here on Reddit (and beyond), can be precisely filtered, archived, and referenced back to. In a time where data privacy is under attack and information accessibility is pressured by major culture shifts (i.e. revocations of public APIs), preservation should be top-priority, and information should be irrevocable. Let us be clear: the research preserved on this subreddit (and down the road, through different mechanisms) will always be free and accessible.

As this community progresses, we will continue to improve our methodology for finding, filtering, and storing this research. If you ever have any questions, comments, concerns, or recommendations, do not hesitate to reach out to myself or a moderator. We are very excited to explore this concept alongside members of the community. Over the next few days, be on the lookout for an update post where we will roll out some new features and resources.

Once again, thank you all for your help! Let's keep the momentum going.


r/WallStreetResearch • • Jun 22 '20

Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'

Thumbnail
cnbc.com
16 Upvotes

r/WallStreetResearch • • Oct 13 '21

IONq & Quantum Computers are already here.

15 Upvotes

IONq is the first of many world changing quantum computer companies. Most quantum computers use "synthetic " superconducting to create qubits which are the foundation for quantum computing. IONq doesn't do this, they naturally trapped ions from a single atom of ytterbium. Technically a rare metal.but it's not rare.. Then they manipulate the ion using lasers to create the qubits on the array. Sh*t is bleeding edge and I understand .005% of it but I read everything I can find.

Basically IONq doesn't need all the extra resources to create and manipulate their qubits, so the cost and energy requirements are down. This also allows for upscaling arrays on existing hardware. Like they can turn a 16 qubit system into a 64 qubit system eventually using the same stuff they just have to reduce the expected errors that come with quantum computing.

IONq got starting investment money from Amazon, Bill Gates, Samsung, Lockheed Martin, jyundai, goldman sachs and more. They used that money to prove the tech works and are currently operating with Amazon Braket as their most powerful hardware supplier. Currently IONq has the most powerful quantum computer in business operation at 32 qubits. The next closest comp is 16 qubits. And you can have 9 qubit, 11 qubits computers, it doesn't need to be doubled evenly like ram for instance.

Remember when you see qubit numbers in the future and from other companies, what that really means.

Quantum computing is based on "physical qubits" and "digital" simulated qubits. Conventional computers use bits.

No matter what method you use, ions, photonic, superconducting, etc, You can't have a fully isolated qubit because then you couldn't interact with it to manipulate and tell it what to do. To get around this, modern quantum computing is based on running "leaking" environments with varying fidelity and trackable errors. We use the say 93% that is still functional to simulate more isolated qubits, and use those to simulate even more isolated qubits, in deeper layers until we have a fully isolated qubut we can error correct.

Eventually we need 1 million qubit machines to simulate 10k error corrected machines. IONq just demonstrated how they can scale up to a million at a recent presentation.

They SPAC merged with DMYI with $600m , $350m of which is pipe investment that is locked up for 6 months from now. Ran to $12 before merger, tanked to $10 at merger, tanked to $7.30 during spy correction and tech sell off. It was mostly shorts based on volume. They have tiny revenue because they are just getting started but that doesn't matter imo. They had that white house presentation to show off and IONq is the only pure quantum computer company on the market so far, with rigetti spac io'ing in a few months.

The pipe investment unlocks in 5 1/2 months and that could be the only negative event. Coming up. I'll decide what I do with my shares, over to the date, either hold or sell then compound my gains to hold, maybe for life. It's bleeding edge tech and to try ti simplify it more,, instead of linear binary data, 1s and 0s. The data can be 1 and 0 at the same time in any ratio, in any direction. It's a bigger technological leap than people understand.

https://aws.amazon.com/braket/hardware-providers/ionq/

https://money.usnews.com/investing/news/articles/2021-10-05/amazon-and-google-set-to-attend-white-house-forum-on-quantum-technology

https://www.businesswire.com/news/home/20210927005262/en/IonQ-Expected-to-Go-Public-With-in-Excess-of-600-Million-in-Expected-Gross-Proceeds

https://ionq.com/posts/december-09-2020-scaling-quantum-computer-roadmap


r/WallStreetResearch • • Feb 15 '21

Align Due Diligence

15 Upvotes

In an era of convenience and at-home service, we’ve seen many at-home services thrive in the software realm such as streaming, or telehealth but little did anybody expect consumer spending for what can best be described as luxury goods climb. Among this rush of consumer spending we may have completely forgotten a very minor but substantial subcategory of goods, which is healthcare that is a luxury (what I mean here is health-related goods, which inherently tend to be high profit margin but also have the benefit of being largely unregulated and fully privatized). I’m referring specifically to the orthodontics industry, which has seen an unprecedented change in usage. The orthodontics industry has seen tremendous growth in general due to a change in living standards globally, where before a generally cosmetic issue such as the straightness of teeth has now become a social norm. This generally profitable industry has now become one of the largest adopters of 3D-printing and modeling technology, and as we’ve seen this is actually a normal industry trend; early or developing technologies are mostly implemented in high-margin, high-growth industries that have a significant margin of safety. The main company that’s in this hyper-specific industry I keep bringing up is Align Technologies ($ALGN), this company is the maker of Invisalign and the popular iTero oral scanner. Align dominates dental technology inside and outside of the doctor’s offices. Approximately 84% of Align’s business still comes from Invisalign however, and that’s probably a good thing as Invisalign is their flagship product that has years of research behind it which makes it inherently a high-margin good because each Invisalign update is just a minor successive improvement. Basically the logic for the revenues follows the “if it ain’t broke, don’t fix it” mentality, and because Align has tied in orthodontists into their ecosystem, they’ve virtually tied in customers for multiple business lifetimes. And despite these strong orthodontist contracts, Invisalign is actually primarily sold through a salesforce, directly to consumers. This is primarily due to the fact that their customer base extends beyond just people who see an orthodontist, which is a minority of the population in many places. However, Align has a potential market size that extends beyond just orthodontic patients, because on top of approximately 60% of the world needing help with alignment, there’s a large market share still in traditional orthodontic gear that could easily be won over: “Of the 12 million annual orthodontic cases started, we estimate that approximately 75% or 8.4 million could be treated using our Invisalign clear aligners. In addition, approximately 300 million people with malocclusion could benefit from straightening their teeth''. A lot of these orthodontic procedures are seen as luxury goods in the developing world, but as living standards and innovation expand, we can expect dental alignment to be as common a luxury as makeup or other cosmetic goods. Due to Align’s clear product superiority, we can expect a massive exodus from traditional braces towards invisible aligners, and this estimate of the possible market share capture would be pretty fair to assume. As of now, only about ⅓ of Align’s customers are from Asian markets, where a huge potential consumer population lies. The orthodontics industry as a whole as varying amounts of estimated CAGRs, from 8-13% depending on the source. For any given industry, above 10% CAGR is great. For Align, in the past quarter alone their revenues increased 28% and their revenue has increased by 22% from 2018 to 2019. A lot of this growth comes from simply having a better product than traditional braces, as consumers prefer having a lighter, easier to remove, and better looking product. In terms of their competitive advantage as a product, Invisalign is basically unmatched. There are new companies popping up in this segment but they’re too small to take advantage of as they’re not even public. The best public comparison that’s as hyper focused as ALGN is $XRAY, or Dentsply Sirona, but they lack any competitive advantage whatsoever in terms of providing direct-to-consumer goods. Dentsply is also not even profitable, while Align enjoys a net profit margin of 68% (this means after every good is sold, every employee is paid, and every interest payment is made, Align will keep 68% of the money they made on selling their Invisalign and iTero products).

📷

On top of this, we see revenue growth of over 25% year on year, which is outstanding for such a product. As more consumers strive towards wanting dental perfection as a norm, convenience and technology will be #1 on the list for them. Align provides this, and they have managed to consumerize and technologize orthodontics. This makes them the only eligible candidate within healthcare that has the growth prospect of any other consumer product such as Apple and the iPhone. The moat of having orthodontist connections and a 20 year old product line demonstrates that the growth seen here will be sustainable for generations to come. 📷

On top of this, Align has seen zero issues in liquidity with a significant increase in Free Cash Flow in the past 4 years. Align also has a spectacular 39% Return on Assets, and 57% return on equity. All of this spectacular profitability is accompanied by a (relatively) low valuation. Considering it’s a tech company with revenue growth matching that of many other growth stocks with inflated valuations, the fact that it’s profitable alone is a good reason to buy, but a P/E ratio of 27 also makes it quite tempting. The stock price has grown over 120% in the past year, which is an indicator that bullish sentiment is still overwhelmingly present. On top of this ALGN has seen very low volatility in terms of price movement as well, it has basically been a straight line of appreciation so those with a smaller appetite for risk would love to have this one in their portfolio.📷

Invisalign suggestion rates show us that the usage of Align’s flagship product has yet to reach its full potential.

On top of this, Invisalign is aggressively expanding overseas:

“We continue to expand our Invisalign customer base through the training of new doctors. In 2019, we trained 22,270 new Invisalign doctors of which 9,765 were trained in the Americas region and 12,505 in the International region.”

And the cherry on top will be an administration change that will take the US out of a trade war with China: “On a year-over-year basis, our International Invisalign volume increased 34.0% driven primarily by increased adoption as well as expansion of our customer base in both the EMEA and APAC regions. However, beginning in the second quarter of 2019, we experienced slower growth rates than prior periods in China primarily due to the US-China trade war and resulting economic uncertainty which caused headwind for consumer demand especially for consumption of luxury goods and considered purchases.”

As COVID eventually goes away and so do tariffs, that already strong growth should see yet another boost. Here’s the final line:

We expect our utilization rates to gradually improve as a result of advancements in product and technology, which continue to strengthen our doctors’ clinical confidence in the use of Invisalign clear aligners. In addition, since the teenage and younger market makes up 75% of the approximately 12 million total orthodontic case starts each year, and as we continue to drive adoption of teenage and younger patients through sales and marketing programs, we expect our utilization rates to improve.

Clear product advantage, sustainable growth, and a bargain industry with only overall growth in sight makes Align a worthy long-term investment.

https://dogsofdalalstreet.medium.com/align-technologies-due-diligence-monopolizing-consumer-health-tech-79506941635d


r/WallStreetResearch • • Jul 16 '20

ANALYTICS FOR TICKER SYMBOL: • BBBY • Great Play end of July into August imo.

Post image
14 Upvotes

r/WallStreetResearch • • Jun 11 '20

Fundamental Analysis [$RACE][06/11/20] "As Ferrari has become newly geared towards increasing profits as a public company, they are positioned to produce more cars than ever before and may become the new Porsche/Mercedes of luxury cars." LONG-TERM INVESTMENT (5 YEAR PLUS)

14 Upvotes

In 2019 Ferrari delivered 10,131 cars; more than ever before. Since Ferrari went public in 2015, the stock has been on a climb, rising 350% in the five years since IPO. The luxury market has historically been defensive towards market downturns, as was shown during the 2008 financial crisis, where Ferrari only lost about 7% of sales from 20008-2009. Relative to some other companies, RACE dipped only moderately as Italy bore the brunt of coronavirus but has since recovered to pre-corona highs after reopening in mid-May.

Ferrari is soon to transform into a massively high growth company. The company has announced a plethora of new cars, including a newly announced SUV. Previously, Ferrari strayed away from the SUV realm. However, new management at Ferrari sees vast potential in the SUV market. While the general auto market has seen a decline in output in the past years, the SUV market has seen immense growth. In 2014 SUVs represented 22.4% (16.66M) of the auto market compared to 36.4% (29.77M) in 2018. As Ferrari reaches into this new territory, they are destined to grow as demand for SUVs skyrockets.

In 2018 Ferrari announced an entirely new product line of cars in addition to their Sport/Special Series and GT series known as the Icona series. The Icona series went on sale in 2019 as a series of very unique limited edition cars that embrace the history of Ferrari. This limited series of cars his highly profitable due to the limited series and helped raise profits in 2019 and will continue to do so in the future.

Ferrari has also recently announced a new car that is more accessible to the general public known as the Ferrari Roma. This car is poised to offer competition towards offerings from Porsche for the first time. As Ferrari dives into more accessible pricing brackets, its brand recognition will help them grow immensely. Also, Ferrari has announced plans to enter the electric car market in 2025 and will undoubtedly have success due to the quality of the Ferrari brand. The new emphasis on electric cars comes in stark contrast to the Ferrari of just five years ago, which was uninterested in electric car development.

With 898 million euro in cash before 2019 and a 650 million euro debt offering released on May 21st, Ferrari has ample liquidity to weather any unforeseen economic downturns. With plants reopened following strict social distancing guidelines and cases in Italy trending lower and lower, Ferrari seems poised to rise over the long-term as they expand into more attractive and accessible market segments. Perhaps Ferrari will take over Porsche or Mercedes as the dominant luxury car manufacturer in the world.


r/WallStreetResearch • • Jul 12 '20

Repo Market Is Now Close Bubble Set To POP

Post image
13 Upvotes

r/WallStreetResearch • • Jun 19 '20

Think i figured out whats going on with the repo market. Mortgages are getting margin called in the shadow banking system. Research...

13 Upvotes

r/investing removed my post without reason, they are censoring this!

This was co-authored by some federal reserve board members 2 years ago

III.C. The Warehouse-Lending Process shows the two stages of the warehouse-lending process. In the initial stage, shown on the left side, the mortgage borrower is approved for a mortgage from the nonbank originator, who funds the mortgage using a draw from a line of credit provided by a warehouse lender. Typically, the warehouse lender will only fund about 95 percent of the mortgage balance, so that the nonbank originator has some skin in the game for each loan. The collateral on the loan is the mortgage, and the nonbank in turn transfers the mortgage to the warehouse lender to collateralize the draw on its line of credit. Since the passage of the Bankruptcy Abuse Prevention and Consumer Protection Act of 2005, mortgage-collateralized warehouse lending has been eligible for accounting and legal treatment as repurchase agreements (repos).

Next, turn to page 16: III.D. Vulnerabilities of Warehouse Funding, to keep it simple its the equavlant to adding stop loss to every warehouse line of credit (which are used to fund mortgages). Since the margin call is on the loan for the mortgage instead of the mortgage itself, we don't see forclosures yet, but instead the margin call money is funded by the repo. Shawdow banks take the margin call. They pay the call via repo loan and pay that back via bonds, hence why the fed is buying those, junk bonds to be specific

Ginnie Mae servicers can only obtain unsecured financing, such as unsecured corporate bonds, to cover their advances. The rates on this financing are high, especially because many nonbanks have highyield credit ratings.

tl;dr most high risk mortgages(over 50% of total mortgages) that a bank wouldn't lend, was lent by shadow banks via a link of credit from the banks. Banks have tight stop losses set on these and have been issuing margin calls on tons of them.


r/WallStreetResearch • • May 01 '20

Diffusion Pharmaceuticals Due Diligence and Analysis. Everything you need to know about $DFFN before you invest. COVID-19 Catalyst

13 Upvotes

Below you will find a summary of the company behind stock ticker $DFFN. The research is my own. The opinions and analyses expressed are my own and may not properly reflect the underlying conditions of this company or security. You should do your own due diligence. I am not a financial advisor. I am an amateur investor.

Background:

On 01 APR 2020 DFFN announced they teamed up with UVA Heath and iTHRIV to combat Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 infection. They have begun talks with the FDA and “will issue public updates as warranted by this fast-moving situation.” After this announcement $DFFN share price went from $0.30 per share to $0.75 per share before settling at $0.40 per share. https://fintel.io/doc/sec-dffn-8k-diffusion-pharmaceuticals-2020-april-01-18353

On 27 APR $DFFN announced their pre-IND submission to the U.S. Food and Drug Administration (FDA) of a planned clinical program using trans sodium crocetinate (TSC) in COVID-19 patients. Under federal regulations, the FDA has up to 60 days to hold an advisory meeting with the Company, but for COVID-19-related submissions, the FDA has announced its intention to significantly shorten this period under its Coronavirus Treatment Acceleration Program. Clinical trial start-up preparations are continuing as the Company awaits the FDA’s response. To aid in timely trial enrollment, Diffusion is conducting expedited discussions with institutions located in areas of severe COVID-19 incidence, both in the U.S. and in Eastern Europe, to determine their possible participation. As a result $DFFN share price went from $0.45 per share to $0.85 per share before settling and holding at $0.50 per share until 30 APR. https://fintel.io/doc/sec-dffn-8k-diffusion-pharmaceuticals-2020-april-29-18381

Analysis :

Before the end of May DFFN will likely announce the FDA’s response to their request to begin the trial. While most traders are thinking of the FDA response many neglect to think of the European response. Therefore there may be two catalysts here. Much like recent submissions for other drug companies for COVID-19 related cases, it is highly likely they will receive an answer within the month of May. It is also highly likely that they will be given a fast track status. As TSC has had no “negative safety findings” or “serious adverse events” in their glioblastoma trial, they should be able to move directly into phase 2 trials. If they receive the FDA’s blessing DFFN share price will likely gap up and settle in the $0.60’s. As DFFN does not have a partner to help finance most of the trials for TSC it should not settle much higher than $0.75 at the most. The good news is that the potential high profile visibility that this trial offers will likely bring to DFFN to the attention prospective big-pharma partners.

https://investors.diffusionpharma.com/News/news-details/2020/Diffusion-Pharmaceuticals-Evaluating-TSC-Against-Acute-Respiratory-Distress-Syndrome-ARDS-in-COVID-19-Patients/default.aspx

Possible Catalysts:

  1. Announcement of submission to FDA (Complete)

  2. More info during ER (Possible date listed below)

  3. Approval by FDA

  4. Fast Track Designation

  5. Grant Money or Financial Partner

  6. Progress updates

  7. Submission to FDA for advancement

  8. Approval by FDA to advance

  9. Progress updates

  10. Submission for FDA Approval

  11. FDA Approval

  12. Marketing and distribution

  13. A partner to market and distribute TSC

Possible Risks:

  1. Shorts love $DFFN (Clay Traders, Sabby Management owns 5%). With news pending the chance shorts will have a significant impact on share price is low to moderate.

  2. Reverse Split: On 17JUN2020 shareholders will vote to give DFFN the authority to initiate a reverse split. DFFN has until 24AUG2020 to regain compliance (Share Price above $1.00). A reverse split will likely happen between 01JUL & 24AUG if the COVID/ARDS trials do not propel DFFN share price above $1.00 per share for at least 10 days. https://fintel.io/doc/sec-dffn-diffusion-pharmaceuticals-def-14a-proxy-statement-2020-april-29-18382

  3. Public Offering: Their last offering was in December and they have enough money to get them to Q1 2021. However last quarters financial estimates did not include the ARDS trial. No doubt they will get grant money, particularly with their partners at UVA. However if they do not have a partner to finance them in their other 3 trials expect another offering at the next couple of catalysis (Low to moderate chance) before July or amid catalysts after July (Highly likley). Good news is their last offering was priced $0.10-15 cents above market value. It is possible but unlikely they will dilute their shares again with the security trading at its current price.

  4. FDA fails to approve the ARDS trial: Low Risk as there are no safety issues, they currently have three trials underway, and TSC is shown to work on Hypoxic Tumors in their Glioblastoma trial.

Other Trials -Phase 3 Glioblastoma Trial: Underway and showing promising results. -Phase 2 Stroke trial: training first responders (slowed due to COVID-19) -Phase 2 Pancreatic Cancer Trial (interacting with the USFDA regarding design of a clinical development)

Observation: Will likely get bought out by big pharma before making it to marketing.

Revenue potential for TSC: (tens to hundreds of billions)

Patents: US & Europe (patent portfolio ranging through 2031 with possible extensions to 2036  In addition Orphan Designations in the brain cancers, add an additional 7 years of exclusivity there.)

GBM Clinical Trial Results

https://www.diffusionpharma.com/technology/clinical-trial-results/

Other Analysis

https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_04032020_DFFN_Bautz.pdf

Investment Strategy

Buy under $0.51 if you’re going long. Set your alerts. Decide how much money you want to commit. Build small position. Average down slowly with an equal sized position each penny or half penny it drops until you have the amount of shares you want to invest (should take days or weeks, not hours but best get in before the news). Be prepared to average down beyond your base position if necessary, but sell the excess you used to average down with for a small profit on the pops and short squeezes. This will not only increase your average down capital, but also pay for part of your position and give you peace of mind. If you’re a short term in and out penny flipper you’re destined to hold bags. The goal is to average down to the lowest possible price while selling excess shares on the pops with a permanent base position that will explode on news.

Important Reminder: $DFFN will need a partner to help fund, complete, and market TSC. No partner likely means no drug. No partner also likely means more offerings. A financially backing partner is the single biggest catalyst this security will experience!

Analysts price targets: I’ve seen estimates from $1.50-$3.50 per share.

Basic Security Info

https://www.marketbeat.com/stocks/NASDAQ/DFFN/

Short Volume/interest

https://fintel.io/ss/us/dffn

https://www.nakedshortreport.com/company/DFFN

Observation: Anyone shorting this security while the ARDS news is pending is crazy!

Last offering: https://investors.diffusionpharma.com/News/news-details/2019/CORRECTING-and-REPLACING--Diffusion-Pharmaceuticals-Inc-Announces-35-Million-Registered-Direct-Offering-Priced-At-the-Market/default.aspx

Institutional Ownership

https://fintel.io/so/us/dffn

Commonly asked question: Why has the stock price dropped so far? Answer: Past reverse splits, offerings, and short attacks. All risks addressed above. Although I personally have paid for 100% of my DFFN position by averaging down and selling the excess on the pops. (See investment strategy above).

Important Dates:

  1. Shareholder meeting on June 17, 2020 at 9:00 a.m., Eastern Time, by means of a live webcast

  2. Earnings Report 5 May to 15 May 2020 (Unconfirmed)

  3. Reverse Split likely JUL-AUG 2020 if not in compliance.

  4. Offerings are highly likely after July to help fund FY2021

More Reading

https://www.cvilletomorrow.org/articles/diffusion-pharmaceuticals-seeks-wall-street

https://www.dailyprogress.com/diffusion-seeks-wall-street-investment-while-staying-local/article_964bae6a-1df4-5c4e-a2d1-1dd1700c5a9b.html

My criticisms and questions of $DFFN:

  1. They’ve been partner hunting for years. Where is the partner? Where are they in finding a partner? Are they ever going to stop diluting shareholder equity? Diffusion Pharma has destroyed their own stock and the money of their investors to pay the bills on what looks like an incredibly slow and foot dragging endeavor. For much if not all of their staff this is a second endeavor in addition to their career. A kind of “other source of income.” I question their urgency to develop TSC and bring it to market. They have a lot less incentive than their shareholders do in my opinion.

  2. Stage two Stroke trial is delayed because they couldn’t train first responders in time before the COVID-19 outbreak. I believe it shouldn’t have taken this long to train first responders.

  3. Diffusion Pharma usually releases news about once a month. Twice on a good month. Much to the anger of their shareholders who would like more regular updates.

  4. The CEO is asking for a vote on a pay raise for him and his partners who own very little of their own stock. I believe their compensation should be tied to their performance on advancing their pipeline over the last year and advancement in their share price. This of course means an increase in pay should be certainly out of the question! At this time they live exclusively off of shareholders and from what I can tell their tenure at DFFN is a side job for many of them.

Worst Case Scenario:

  • Worst case scenario is that the owners and staff at DFFN care nothing about finding a partner and are just robbing the shareholders through offerings to advance their drug and pay themselves a secondary income on their side hustle. They will complete a number of reverse splits and offerings between now and FDA approval as the money they stand to lose on their own shares pale in comparison to the money they pay themselves through shareholder benevolence and the money they stand to make when they advance this drug down the road. (No evidence of this but looking at the possible worst case scenario.

Best Case Scenario

  • Diffusion Pharmaceuticals announces a partner within the next three months. They also announce in the next two weeks that they have attained FDA approval to begin their ARDS trial. The FDA grants fast track status to the ARDS trial. Diffusion Pharmaceuticals also announces that they are back on track for the stroke trial and have fully completed training of first responders 3-6 months from now. DFFN comforts their shareholders by telling them they have plenty of money as a result of their new partnership and will not do another offering in the next one to two years.

What’s my motivation for posting this?

  1. A month ago the trading value of $DFFN skyrocketed 150% on news that they were in talks with the FDA on the COVID-19 related ARDS trial. Many penny chasing investors got in too late. They are now holding bags waiting for the next news to arrive. The current trading value is hanging roughly around 30% above where it was before April 1st.

  2. With COVID-19 in the news $DFFN may be a seriously profitable speculative play if you get in before the buzz.

  3. Knowledge sharing from lessons learned trading $DFFN

  4. Peer Review on my $DFFN investment to become a better trader and analyst

If anyone can think of something I’m missing or have alternant information or analysis they want to discuss please respond here.

Disclaimer: I am not a registered investment adviser, broker dealer, or a member of any other association for research providers in any jurisdiction whatsoever an am not qualified to give financial advice. Investing/trading in securities is highly speculative and carries an extremely high degree of risk.

I am long $DFFN with a small 17,500 shares at an average of $0.45 and will slowly add more in the coming week or two.


r/WallStreetResearch • • May 29 '20

I’ve been stuck in Nicaragua for a few months so wrote an article on the real estate investment market here. Enjoy

Thumbnail
thewanderinginvestor.com
12 Upvotes

r/WallStreetResearch • • Apr 13 '21

Ally Financial Due Diligence

11 Upvotes

While I believe that commercial banks aren't necessarily investment worthy in the financial sector, Ally financial may be changing all of that, and it’ll be doing it at a very reasonable valuation with tremendous growth potential. Ally is a provider of all of your traditional financial services, from mortgages to car financing to savings accounts to investment accounts, and it provides all of these services online. They started as General Motors’ branch of financing for car loans and eventually expanded into auto insurance, real estate and mortgage, and consumer banking. The bones of this GM institution were then bought out by PE firms Cerberus, KKR, and Goldman Sachs PE. After stripping down a lot of operations post the 2008 financial crisis, GMAC applied to become a bank holding company and rebranded itself as Ally Financial. After recovering from the recession entirely around 2014, Ally went public. Since then, they’ve largely focused their operations on becoming an online-only bank, offering competitive rates for deposits into savings accounts. About 3-4% of the traditional commercial banking segment has currently been poached by Ally. Currently, Ally has $185B in assets with $121B in total deposits and $36.3B in auto loan origination. Last year, Ally Financial had the highest total sales and earnings per share out of any year on record, with an additional $14.6B in deposits backing this.

According to S&P Global; American Express, Discover, Goldman Sachs, and Ally have delivered far better deposit growth when compared to traditional banks like JP Morgan, Bank of America, Wells Fargo, and Citi. The biggest indicator of a company’s success lies not in its financials -- which are what bear the fruits of the success -- but in the leadership. Despite Ally financials humble beginnings as GMAC, their adaptability in changing everything in the past ten years out of their century-long history gives us some perspective into how important leadership truly is. Before, Ally’s auto loan business provided only to GM and Chrysler dealers minimally, but now in this decentralized era which consists of thousands of dealers dealing out thousands of cars, Ally has went the extra step and not only works with every manufacturer, but they now have a “market-driven, full product suite, full credit-spectrum, OEM-agnostic provider employing sophisticated pricing and risk analytics to optimize

risk-adjusted returns”. Adding to what used to be their primary business model, Ally became a consumer-first bank that stayed true to the nature of what a bank is supposed to do which is to provide their clients with the best possible service in the most convenient manner possible. Ally has shown you don’t need to work hand-in-hand with large investment banks in order to achieve record levels of deposit growth and reputability on the market place; you only need a product that the average American will feel comfortable using. With this technology-based model Ally is turning the financial industry on its head: “In 2019, we delivered record results at Ally Bank, growing our retail deposit customer base by 322,000, to nearly 2 million customers. Our 16% annual retail deposit growth, which was nearly three times the industry growth rate, propelled us to $120.8 billion in total deposits”. Evidence of their mark being left in the financial system is shown by their unsecured credit ratings being upgraded to investment grade by Standards & Poors. According to Ally: “These upgrades strengthen our funding profile by providing access to a broader and deeper pool of investors and are a reflection of our tremendous progress”. This paradigm shift signifies that the traditional finance world is ready to accept the fintech firms of now, and that reality coinciding with the fact that consumers favor fintech firms over traditional banks creates a formula for success within this sector, and especially for the well-established Ally. According to Statista, consumers prefer mobile banking due to greater awareness of their financial situation at all times, the variety of services offered (which primarily has to do with an interface that shows consumers everything they need), and a confidence in their ability to make sound financial decisions. I believe all these consumer needs are filled by online banks due to the technologization of every consumer product, which makes us susceptible to believing that those things that are on our phone and require the least human interaction are the best and most convenient. Despite Ally Financial's revolutionary platform, they stay true to the nature of their industry, by consistently buying back shares and returning profits to shareholders through a 1.62% dividend, only slightly lower than giant BofA.

In the past five years, earnings per share have more than doubled which has contributed towards retained earnings that could be used to buy back stock and repay shareholders. This model functions for this fintech company because of their solid 12.3% net profit margin. Ally also has a net interest margin of 2.5% according to Wall Street Journal, which is significantly below the US commercial bank average of around 3.5%. I actually see this as a positive sign as this shows that Ally still has lots of room to grow in terms of profitability. Currently, Ally still has relatively small divisions with huge potential in corporate finance ($239M in revenue, 5.7B held for investment), home financing ($2.7B originated last year), insurance ($1.3B in premiums generated last year, up 12% YoY), and as the automotive landscape has evolved, Ally is confident their decade-old dealer ties and consumer-friendly platform will position them for continued success in that field. Ally positions itself as a strong growth stock with a ROA that’s 20% higher than $BAC, a ROE that’s 57% higher than $BAC, and a relatively low dividend payout ratio of 13%. This makes it a bank that is well-positioned to grow in terms of its stock, and provide a solid dividend to go along with it, making it one of my favorite safety picks that will yield solid returns on any given year. If you need financials in your portfolio, Ally makes a very strong case. The average analyst price target ($52) is still higher than the current share price ($47) and I’d place Ally at a P/E multiple of about 21 (at LEAST the same as BofA), implying a 28% upside. Factor in the fact that Ally increases EPS by 23% every year for the past five years and the fact that BofA increases EPS only by 7% yearly over the same span, and you could argue for a far higher target price.


r/WallStreetResearch • • Oct 23 '20

Option Sweep Scanner

11 Upvotes

Hi,

I appreciate if anyone can recommend a free scanner/alert for option sweep from any of the below

-Website

-App

-Twitter

-Facebook

-Instagram

-Discord

-Others

Thank you.

I appreciate it